Recent news: Intralytix, Inc. has entered into a Multiple Project Collaboration Agreement ("MPCA") with The Procter and Gamble Company (NYSE:PG).
"The MPCA sets the stage for Intralytix and P and G to collaborate on the development of bacteriophage (or phage) based technology for a range of applications," stated John Woloszyn, Intralytix's CEO.
"Our phage-based technology is all natural and environmentally friendly and we look forward to this collaboration bringing forth new innovations," Mr. Woloszyn added. The company already has two FDA/USDA approved phage-based products on the market: ListShield™, effective at substantially reducing or eliminating Listeria monocytogenes on food products, and EcoShield™, which is effective at substantially reducing or eliminating E. coli O157:H7 on red meat intended for grinding.
Intralytix, Inc is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health and human therapeutics and probiotics.
For more information, contact Mr. John Woloszyn (410-625-3813 or jwoloszyn@intralytix.com) or Dr. Barbara Miller (513-622-4350 or miller.be@pg.com).
more Intralytix press info

No comments:
Post a Comment